Our research is based on our medical and pharmaceutical background and a bed-to-bench strategy. The team has strong experience in malaria research, from basic sciences to applied diagnosis and treatment, including prospective clinical trials. The group is fully equipped to study clones of malaria parasites and isolates from patients leading to direct proof of concept of our research hypothesis. Among these, the effect of innovative single dose drugs on malaria transmission and disease severity is explored in the lab and during long-term prospective clinical trials in endemic west-African and Asian countries. We are also involved in antifungal stewardship aiming at an optimal use of antifungals through careful selection of agents based on patient profile, target organism, toxicity, cost, as well as the likelihood of emergence and spread of antifungal resistance. In that perspective, we are implementing stewardship programs in health care facilities to limit overuse or misuse of antifungals proven to be responsible for an increase in resistance.